全文获取类型
收费全文 | 15252篇 |
免费 | 1246篇 |
国内免费 | 472篇 |
专业分类
耳鼻咽喉 | 63篇 |
儿科学 | 109篇 |
妇产科学 | 80篇 |
基础医学 | 2163篇 |
口腔科学 | 1501篇 |
临床医学 | 1274篇 |
内科学 | 2257篇 |
皮肤病学 | 256篇 |
神经病学 | 579篇 |
特种医学 | 474篇 |
外科学 | 1968篇 |
综合类 | 1779篇 |
现状与发展 | 3篇 |
预防医学 | 783篇 |
眼科学 | 946篇 |
药学 | 1548篇 |
4篇 | |
中国医学 | 819篇 |
肿瘤学 | 364篇 |
出版年
2024年 | 18篇 |
2023年 | 269篇 |
2022年 | 395篇 |
2021年 | 865篇 |
2020年 | 657篇 |
2019年 | 591篇 |
2018年 | 581篇 |
2017年 | 539篇 |
2016年 | 582篇 |
2015年 | 608篇 |
2014年 | 1014篇 |
2013年 | 1188篇 |
2012年 | 828篇 |
2011年 | 918篇 |
2010年 | 742篇 |
2009年 | 692篇 |
2008年 | 670篇 |
2007年 | 647篇 |
2006年 | 612篇 |
2005年 | 553篇 |
2004年 | 454篇 |
2003年 | 399篇 |
2002年 | 319篇 |
2001年 | 291篇 |
2000年 | 242篇 |
1999年 | 203篇 |
1998年 | 176篇 |
1997年 | 161篇 |
1996年 | 136篇 |
1995年 | 113篇 |
1994年 | 139篇 |
1993年 | 125篇 |
1992年 | 113篇 |
1991年 | 105篇 |
1990年 | 101篇 |
1989年 | 77篇 |
1988年 | 85篇 |
1987年 | 83篇 |
1986年 | 98篇 |
1985年 | 127篇 |
1984年 | 89篇 |
1983年 | 65篇 |
1982年 | 97篇 |
1981年 | 50篇 |
1980年 | 46篇 |
1979年 | 27篇 |
1978年 | 23篇 |
1977年 | 29篇 |
1976年 | 10篇 |
1972年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
7.
Norio Itokawa Masanori Atsukawa Akihito Tsubota Noritomo Shimada Hidenori Toyoda Koichi Takaguchi Atsushi Hiraoka Tomonori Senoh Mai Koeda Yuji Yoshida Tomomi Okubo Taeang Arai Korenobu Hayama Ai Nakagawa-Iwashita Chisa Kondo Katsuhiko Iwakiri 《Internal medicine (Tokyo, Japan)》2021,60(4):507
Objective Pegylated-interferon monotherapy is the standard treatment for patients with chronic hepatitis B; however, the factors associated with its therapeutic effects remain unclear. Methods Patients with chronic hepatitis B were treated with pegylated interferon α-2a for 48 weeks. We evaluated the kinetics of hepatitis B surface antigen (HBsAg) during treatment and follow-up periods and the factors associated with an HBsAg response (defined as a change in HBsAg of ≥-1 log IU/mL from baseline). Results The study population comprised 50 patients. The median baseline levels of hepatitis B virus DNA and HBsAg were 5.00 and 3.40 log IU/mL. The median values of HBsAg reduction from baseline were -0.44 (n=48), -0.41 (n=40), and -0.68 (n=11) log IU/mL at the end of treatment and at 48 and 144 weeks post-treatment, respectively. The rates of HBsAg response were 24.0% and 22.5% at the end of treatment and at 48 weeks post-treatment, respectively. A multivariate analysis identified HBsAg <3.00 log IU/mL as an independent baseline factor contributing to the HBsAg response at the end of treatment and 48 weeks post-treatment (p=1.07×10-2 and 4.42×10-2, respectively). There were significant differences in the reduction of the HBsAg levels at 12 weeks of treatment and in the incidence of serum ALT increase during treatment between patients with and without an HBsAg response. Conclusion These findings suggest that the baseline HBsAg level, HBsAg kinetics at 12 weeks of treatment, and ALT increase during treatment are important factors contributing to the HBsAg response in pegylated interferon α-2a monotherapy for patients with chronic hepatitis B. 相似文献
8.
9.
《The Journal of thoracic and cardiovascular surgery》2023,165(2):750-760.e5
ObjectivesThe reduction of postoperative acute kidney injury in patients undergoing cardiopulmonary bypass surgery using an oxygen delivery-guided perfusion strategy (oxygen delivery strategy) for cardiopulmonary bypass management compared with a fixed flow perfusion (conventional strategy) remains controversial. The purpose of this study was to determine whether a oxygen delivery strategy would reduce the incidence of postoperative acute kidney injury in patients undergoing cardiopulmonary bypass surgery.MethodsWe randomly enrolled 300 patients undergoing cardiopulmonary bypass surgery. Patients were randomly assigned to a oxygen delivery strategy (maintaining a oxygen delivery index value >300 mL/min/m2 through pump flow adjustments during cardiopulmonary bypass) or a conventional strategy (a target pump flow was determined on the basis of the body surface area). The primary end point was the development of acute kidney injury. Secondary end points were the red blood cell transfusion rate and number of red blood cell units, intubation time, postoperative length of stay in the intensive care unit and the hospital, predischarge estimated glomerular filtration rate, and hospital mortality.ResultsAcute kidney injury occurred in 20 patients (14.6%) receiving the oxygen delivery strategy and in 42 patients (30.4%) receiving the conventional strategy (relative risk, 0.48; 95% confidence interval, 0.30-0.77; P = .002). The secondary end points were not significantly different between strategies. In a prespecified subgroup analysis of patients who had nadir hematocrit less than 23% or body surface area less than 1.40 m2, the oxygen delivery strategy seemed to be superior to the conventional strategy and the existence of quantitative interactions was suggested.ConclusionsAn oxygen delivery strategy for cardiopulmonary bypass management was superior to a conventional strategy with respect to preventing the development of acute kidney injury. 相似文献
10.